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Pancreatic cancer has an extremely poor prognosis, largely due to a poor record for 
early detection. Known risk factors for pancreatic cancer include obesity, diet, and 
diabetes, implicating glucose consumption and regulation as a key player. The role 
of artificial sweeteners may therefore be pertinent to disease kinetics. The oncogenic 
impact of artificial sweeteners is a highly controversial area. Aspartame, one of the most 
studied food additives, is widely recognized as being generally safe, although there 
are still specific areas where research is incomplete due to study limitations. Stevia, by 
contrast, has been the subject of relatively few studies, and the potential health benefits 
are based on extrapolation rather than direct testing. Here, we used longitudinal tracking 
of pancreatic acinar carcinoma development, growth, and lethality in a sensitized mouse 
model. Despite exposure to aspartame and stevia from the in utero stage onward, we 
found no disease modification activity, in either direction. These results contribute to the 
data on aspartame and stevia safety, while also reducing confidence in several of the 
purported health benefits.
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inTrODUcTiOn
Pancreatic cancer has one of the highest fatality rates, making it the fourth highest killer in abso-
lute numbers despite being relative rare in incidence (1). A major contributor to high mortality 
is late detection—more than half of pancreatic cancers are diagnosed at a late stage, where 5-year 
survival rates are only 2% (1). This makes identifying the risk factors for pancreatic cancer impera-
tive. Currently, age, smoking, obesity, lack of physical activity, diet, type 2 diabetes (T2D), chronic 
pancreatitis, cirrhosis, and genetic background are all associated with pancreatic cancer risk (2, 3). 
The association of obesity, diet, and T2D with pancreatic cancer illustrates the strong linkage to 
glucose intake and regulation, thereby identifying artificial sweeteners as an important topic for 
investigation.
Aspartame is the most commonly used artificial sweetener. The modified dipeptide of aspartic 
acid and phenylalanine gains it property of sweetness through binding TAS1R2 and TAS1R3 (4). 
The use of aspartame as a food additive originally faced widespread resistance due to carcinogenic 
fears, with increased risk of cancer in some studies of treated rodents (5, 6), although the study 
design has been criticized (7). Epidemiological analysis of aspartame use identified additional 
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risk of lymphoma (8), urinary track tumors (9), and prostate 
cancer (10). However, this risk identification has been small and 
inconsistent, and independent studies have not reproduced the 
same result (11–13). Overall, thorough review of the scientific 
literature has found no robust and convincing evidence for 
toxic effects, including cancer promotion (14–16). Nonetheless, 
aspartame remains controversial (17, 18), especially in the public 
sphere, with prominent media attention given to several anti-
aspartame campaigners.
While much of the criticism of aspartame seems scien-
tifically unwarranted, there are gaps that merit further research. 
Epidemiological studies on aspartame use will always struggle to 
pick up weak disease modification associations, as studies tend 
to rely on self-reported consumption of aspartame-sweetened 
(diet) beverages as the proxy for aspartame exposure, while 
aspartame is actually added to more than 6,000 consumer prod-
ucts. Self-reported diet drink consumption is also not randomly 
assigned and will show correlation with other variables that may 
modify disease. Consumption also changes over time, with past 
consumption much more difficult to assess, so impacts of long-
term aspartame use will be harder to identify. Likewise in animal 
studies, toxicity studies are well designed to pick up strong disease 
induction effects, but since they start with a healthy population of 
animals they are unlikely to identify disease modification effects. 
For a rare disease such as pancreatic cancer, a risk modification 
of even 10-fold increase is thus unlikely to be picked up in most 
studies, driving the need for screening the dietary impact in 
sensitized animal models.
In contrast to aspartame, stevia is widely cited in alternative 
medicine circles to have antitumor properties, albeit with little 
scientific foundation. Stevia is an artificial sweetener extracted 
from the leaves of Stevia rebaudiana, the sweetness of which can 
be attributed to steviol glycosides (mainly stevioside and rebau-
dioside) (19). Stevia and its derivatives were originally banned 
in some countries due to fear of potential carcinogenic proper-
ties; however, toxicology studies found physiological doses to 
be safe (20). The origin for the claim of antitumor properties 
can be traced back to studies of skin cancer formation in mice. 
Using the model of 12-O-tetradecanoylphorbol-13-acetate 
and dimethylbenz[a]anthracene skin exposure, the topical 
application of stevioside mixture reduced the incidence of skin 
tumor formation (21, 22). While this may reflect antitumor 
properties, the experimental result could equally represent an 
anti-inflammatory or even a skin barrier enhancement func-
tion. Regardless, the potential topical properties of stevia cannot 
be extrapolated out to systemic effects after dietary intake. To 
our knowledge, no studies on dietary stevia supplementation 
have been performed on cancer, leaving a critical gap in our 
knowledge which has been filled by inflated claims from alterna-
tive medicine practitioners.
Here, we have sought to determine the impact, if any, of aspar-
tame and stevia on pancreatic acinar carcinoma. With strong links 
to diabetes, glucose consumption and obesity, pancreatic cancer 
remains one of the strongest candidates to detect an oncogenic 
role, either promoting or suppressive, of artificial sweeteners. 
Despite the widespread safety studies of aspartame, the effect on 
pancreatic cancer remains opaque, as the rareness of the disease 
would preclude detection of risk modification in epidemiological 
studies. In the case of stevia, the near-complete absence of solid 
experimental data for dietary supplementation in cancer makes 
in  vivo testing imperative. Through dietary supplementation 
and longitudinal magnetic resonance imaging (MRI), we find 
that neither aspartame nor stevia have any significant impact on 
pancreatic acinar carcinoma development, growth, or mortality.
MaTerials anD MeThODs
Mice
C57BL/6 Ela1-TAg mice were purchased from Jackson (23, 
24). Mice were bred under specific pathogen-free conditions 
and from the time of breeder set-up were exclusively fed on a 
standard chow (ssniff® R/M-H) with either normal drinking 
water, or drinking water supplemented with either aspartame 
(0.035% w/v, Blackburn Distributions Ltd.) or stevia (0.02% 
w/v, Stevia Natura) ad libitum. Male mice were moved to con-
ventional conditions at 7  weeks of age for longitudinal MRI, 
with continuation of the dietary restriction. The study and the 
protocol were approved by the University of Leuven Animal 
Ethics Committee. All experimental procedures were carried 
out in accordance with the recommendations of the University 
of Leuven Animal Ethics Committee. Mouse-weight and blood 
glucose were monitored throughout the experimental time 
course. Mortality indicates the experimental end-point, defined 
as the loss-in-condition sufficient to trigger ethical euthanasia 
(by carbon dioxide).
imaging
A Bruker Biospin 9.4  T Biospec small animal MR scanner 
(Bruker Biospin, Ettlingen, Germany) was used to image mice 
under isoflurane anesthesia. The scanner was equipped with 
an actively shielded gradient set of 600  mT/m using a respira-
tion triggered spin echo sequence with 50 continuous slices 
of 0.5  mm thickness in interlaced mode (acquisition param-
eters: repetition time = 6,000 ms, echo time = 15.9 ms, field of 
view = 4.0 cm × 6.0 cm, a matrix of 200×400, two dummy scans 
and two averages). For radio-frequency irradiation and detection, 
a 7.2 cm quadrature resonator was used.
Data and statistical analysis
Images generated by MRI were analyzed with ImageJ to identify 
tumors (National Institute of Health, Bethesda, USA). Each 
individual tumor was assessed in cross-section for the maximum 
tumor radius, which was used to predict volume using the for-
mula: 4 3/ /( )× ×area area pi . Statistical analysis was performed 
in R (https://www.r-project.org/ version 3.1.2). Cumulative inci-
dence curves were generated using the R package “survplot” with 
fun =  function(x) {1 − x} (25). Survival curves were generated 
using the R “survplot” package and the Kaplan–Meier log-rank 
test, implemented in the R “survdiff ” package (26).
The linear mixed-effect model included the cross level inter-
action between time and diet (i.e., the effect of time is allowed 
to vary between diet groups). We also considered time to have 
variable effects to allow for the change in tumor growth over 
FigUre 1 | longitudinal monitoring of pancreatic tumor growth following dietary addition of artificial sweeteners. TAg+ mice were placed on 
alternative water supplies in utero, and aged on the same exposure to 21 weeks of age. From 7 weeks onward, mice were assessed through magnetic resonance 
imaging (MRI) for tumor detection and size. Representative MRI tumor images for mice with (a) normal drinking water, (B) drinking water supplemented with 
aspartame, (c) or drinking water supplemented with stevia at 8, 14, and 20 weeks. (D) Individual total predicted tumor volume curves for mice with normal 
drinking water (n = 13), (e) drinking water supplemented with aspartame (n = 12), (F) or drinking water supplemented with stevia (n = 15). (g) Grouped total 
predicted tumor volume curves for the data in panel (D–F). P values indicate effect of treatment vs normal drinking water, using a linear mixed-effect model. Time 
corresponds to the age of the mouse.
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time to differ across participants (i.e., explicitly model individual 
differences in change over time). The formula of the model is as 
follows: tumor growth ~ time + diet + time × diet + (1 + time|s
ubject). This model provides a fixed-effect estimate for the interac-
tion between change over time and diet that indicates whether the 
rate of change with respect to tumor growth is significantly dif-
ferent between the regular water and other diets. We considered 
the regular water diet as reference diet and week 7 as reference 
time. These linear mixed-effect models were fitted within each 
sex using the lmer function within lme4 (Linear mixed-effects 
models using “Eigen” and S4) package in R.
resUlTs
no impact of Dietary aspartame or stevia 
on Pancreatic acinar carcinoma Kinetics
Systematic in vivo testing of the potential impact of aspartame 
and stevia on pancreatic acinar carcinoma is required to 
identify any potential health gains or risks. We used the well-
characterized Ela-TAg transgenic mice, which express the SV40 
large T Antigen under the control of the Elastase-1 acinar cell 
promoter, driving spontaneous pancreatic cancer formation, of 
acinar origin (23, 24). This strain, while developing a less com-
mon form of pancreatic cancer, was chosen for the predictable 
tumor development course, allowing experimental testing of the 
impact of exposure while using relatively few mice. To ensure 
high exposure levels, TAg+ mice were placed on 0.035% w/v 
aspartame or 0.02% w/v stevia in the drinking water, without 
access to normal water. This dietary change was implemented 
at the point of breeder set-up, ensuring exposure at the in utero, 
neonatal, juvenile, and adult stage. From 7 weeks of age, TAg+ 
mice on either regular drinking water, drinking water supple-
mented with aspartame, or drinking water supplemented with 
stevia underwent MRI scanning every 2 weeks (Figures 1A–C). 
Following tumor detection, the volume of each tumor was 
calculated over the entire observation period, demonstrating 
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FigUre 2 | no effect of artificial sweetener on pancreatic cancer development. TAg+ mice were placed on alternative water supplies in utero, and aged on 
the same exposure to 21 weeks of age. From 7 weeks onward, mice were assessed through magnetic resonance imaging for tumor detection. (a) Cumulative 
incidence of pancreatic cancer as a function of age at tumor onset, stratified by water supply (standard, aspartame, stevia) in male mice (n = 13, 12, 15). The P 
values were calculated using the log-rank test. (B) Violin plots showing the mean, SD, and kernel probability density of the age at tumor onset under each dietary 
modification. The P values were calculated using two-tailed unpaired t test.
FigUre 3 | additional of high level dietary aspartame or stevia does not modify the growth rates of pancreatic cancer. TAg+ mice were placed on 
alternative water supplies in utero, and aged on the same exposure to 21 weeks of age. From 7 weeks onward, mice were assessed through magnetic resonance 
imaging for tumor size. Individual square root transformed total predicted tumor volume curves for male mice on (a) standard drinking water (n = 13), (B) drinking 
water supplemented with aspartame (n = 12), and (c) drinking water supplemented with stevia (n = 15). Time 0 corresponds to the first detected tumor time-point. 
(D) Violin plots showing the mean, SD, and kernel probability density of the percentage of tumor volume increase every 2 weeks, averaged over the period of 
observation, under each condition in male mice. P values were calculated using two-tailed unpaired t test.
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FigUre 4 | artificial sweeteners do not increase mortality rates in 
mice with pancreatic cancer. TAg+ mice were placed on alternative water 
supplies in utero, and aged on the same exposure to 21 weeks of age. Mice 
were removed from the study when excessive morbidity was observed. 
(a) Representative H&E tumor histology from tumors extracted from male 
mice on standard drinking water, (B) drinking water supplemented with 
aspartame, and (c) drinking water supplemented with stevia, at 21 weeks of 
age. Scale = 100 µm. (D) Kaplan–Meier plot showing the overall pancreatic 
cancer survival in male mice on house, aspartame, and stevia diets (n = 13, 
12, 15). P values were calculated using the log-rank test.
exponential growth (Figures 1D–G). Based on the MRI data, the 
time of first tumor detection was calculated for each mouse. No 
effect of either aspartame or stevia was identified for the cumula-
tive incidence of pancreatic acinar carcinoma (Figure 2A) or the 
age of tumor onset (Figure 2B). These results indicate that even 
with lifelong exposure, high doses of supplementary aspartame 
or stevia do not alter pancreatic acinar carcinoma development, 
with either a positive or negative effect.
Following the assessment of pancreatic acinar carcinoma 
development, the impact of aspartame or stevia supplementa-
tion on the tumor growth rate was assessed. Total predicted 
tumor volumes were normalized for variation in age of onset 
and for the exponential growth rate (Figures  3A–C). This 
allowed the calculation of the tumor growth rate, defined as 
the average percentage of tumor volume increase per 2 weeks, 
for the period from tumor detection to experimental end 
(Figure  3D). By this measure, no alteration in the tumor 
growth rate was observed in mice given either the aspartame 
or stevia supplement. Finally, the effect of both artificial sweet-
eners on tumor histopathology and tumor-induced mortality 
was assessed. No systematic changes in histolopathology 
were observed (Figures  4A–C), and no increase in tumor-
induced mortality over standard drinking water was observed 
(Figure  4D). Most TAg+ mice on standard drinking water 
survived for the entire observation period, limiting the abil-
ity to detect decreases in tumor-induced mortality; however, 
together these results argue against any profound effect of either 
aspartame or stevia on pancreatic acinar carcinoma growth or 
mortality induction.
DiscUssiOn
Aspartame is one of the most tested of all food additives. The 
compound is rapidly metabolized into the constituent compo-
nents (common amino acids) and is not found in the blood or 
urine of individuals that ingest it (27). This makes it unlikely to 
have any major carcinogenic effect, and, indeed, a meta-analysis 
of rodent testing indicates its safety (15). Despite this, the public 
concern over aspartame, divorced from scientific basis, is suf-
ficient that major food companies have removed the artificial 
sweetener from selected products and replaced with alternative 
compounds (which, in the case of stevia, are less well studied than 
aspartame itself) (28). While this reaction is not proportional 
to the data, there are areas where more research is legitimately 
required. Pancreatic cancer is one of these areas, owing to the 
link with dietary glucose consumption and regulation. Our study 
demonstrated no detectable impact of dietary aspartame with 
pancreatic acinar carcinoma risk, using a well-defined sensitized 
rodent model.
Our results here also demonstrated no impact of dietary 
stevia on the kinetics of pancreatic acinar carcinoma. This 
is seemingly in contradiction with in  vitro data from several 
laboratories, which demonstrate that various S. rebaudiana 
extracts have antiproliferative and proapoptotic properties 
on cancer cell lines (29–31), including on the pancreatic 
cancer cell lines MiaPaCa-2 (32) and BxPC-3 (33). However, 
when extrapolating to the physiological context, the process 
of digestion needs to be taken into account. For example, 
stevioside induces apoptosis in cancer cell lines in  vitro (34), 
but a study of the human intestinal metabolism of stevioside 
found rapid hydrolyzation to steviol (35), and thus any potential 
anti-oncogenic properties of stevioside is unlikely to be felt 
outside of the gut. It is therefore likely that the pharmacologi-
cal properties of studied S. rebaudiana extracts demonstrate 
a lack of physiological efficiency due to the exceeding local 
concentrations that would be generated.
Finally, it is worth noting that our study only discounts 
a direct role for dietary aspartame and stevia in modulating 
pancreatic acinar carcinoma, which in turn is a rare sub-
type of total pancreatic cancers (although with a high total 
mortality burden). Use of the precautionary principle may 
still advocate a limitation on the use of artificial sweeteners, 
even with negative data (17, 36). In our opinion, however, the 
precautionary principle in this case comes into direct conflict 
with a harm minimization approach. As artificial sweeteners, 
the main utility of both aspartame and stevia is as a substitute 
for sugar (37). Patient data suggests that consumption of sugar-
sweetened beverages increases the risk of pancreatic cancer 
(38). Thus, regardless of the (lack of) direct bioreactivity of 
aspartame and stevia, when these compounds are used as 
a substitute for glucose, rather than an additive, they are 
likely to strongly reduce the risk of pancreatic cancer. The 
most pertinent question for the health impact of artificial 
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sweeteners may there be the degree to which they substitute 
for sugar, a question perhaps even more controversial than 
the carcinogenic risk (39).
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